Mutated IgHV1-69 gene usage represents a distinct subgroup associated with indolent disease in chronic lymphocytic leukemia
Authors:
- 1 January 2008
- journal article
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 49 (4) , 763-768
Abstract
Biased IgHV gene usage in chronic lymphocytic leukemia (CLL) is well documented and suggests antigen involvement in leukemogenesis. IgHV1-69 is one of the most frequently rearranged IgHV genes in CLL and the majority of IgHV1-69 cases lack somatic hypermutation and display poor prognosis. However, its independent prognostic impact remains uncertain given reports showing a low proportion of mutated IgHV1-69 cases and stereotyped IgHV1-69 subsets with divergent clinical outcome. We assessed the frequency and clinical significance of IgHV1-69 gene usage in a cohort of 330 CLL patients. Functional IgHV1-69 gene rearrangements were detected in 32 cases (9.7%), 31 of which were characterised further. Seven (22.6%) were found to have undergone somatic hypermutation. This subgroup had shorter and more diverse complementarity determining region 3 (CDR3) sequences compared with unmutated IgHV1-69 cases. In addition, mutated IgHV1-69 gene status was associated with lower cell surface CD38 expression and less progressive disease as monitored by Binet staging, lymphocyte doubling time and requirement of chemotherapeutic intervention. To conclude, we present data confirming that IgHV1-69 gene rearrangements in CLL are not exclusively associated with unmutated IgHV status. In addition, we show that a somatically hypermutated subgroup may demonstrate more indolent characteristics despite the general association of IgHV1-69 gene usage with aggressive disease.Keywords
This publication has 28 references indexed in Scilit:
- VH3–48 and VH3–53, as well as VH3–21, gene rearrangements define unique subgroups in CLL and are associated with biased lambda light chain restriction, homologous LCDR3 sequences and poor prognosisLeukemia Research, 2007
- Identification of a gene on chromosome 12q22 uniquely overexpressed in chronic lymphocytic leukemiaBlood, 2006
- ZAP‐70 mRNA quantification in B‐cell chronic lymphocytic leukaemiaEuropean Journal of Haematology, 2006
- CD38 expression level and pattern of expression remains a reliable and robust marker of progressive disease in chronic lymphocytic leukemiaLeukemia & Lymphoma, 2006
- The LPL/ADAM29 expression ratio is a novel prognosis indicator in chronic lymphocytic leukemiaBlood, 2005
- Evidence of biased immunoglobulin variable gene usage in highly stable B-cell chronic lymphocytic leukemiaLeukemia, 2004
- ZAP-70 expression and prognosis in chronic lymphocytic leukaemiaThe Lancet, 2004
- ZAP-70 expression is a prognostic factor in chronic lymphocytic leukemiaLeukemia, 2003
- Chronic lymphocytic leukemia patients with highly stable and indolent disease show distinctive phenotypic and genotypic featuresBlood, 2003
- ZAP-70 Expression as a Surrogate for Immunoglobulin-Variable-Region Mutations in Chronic Lymphocytic LeukemiaNew England Journal of Medicine, 2003